Literature DB >> 8195455

Physical disability and social phobia.

E L Oberlander1, F R Schneier, M R Liebowitz.   

Abstract

The DSM-III-R excludes persons with socially phobic symptoms secondary to axis III conditions from the diagnostic category of social phobia. This exclusion exists without empirical basis. A series of eight clinical cases is presented in which patients suffered from excessive levels of secondary social anxiety relative to their disfiguring or disabling physical conditions. All subjects had a good response to the monoamine oxidase inhibitor phenelzine, which enabled them to live in a less-inhibited and less-restrictive manner. Their medication response to monoamine oxidase inhibitors parallels the psychopharmacologic response patterns of generalized or DSM-III-R social phobics. This study suggests a novel application of the drug phenelzine for a patient group formerly overlooked with regard to treatment options. The similarity of this group's psychopharmacologic responsivity and clinical characteristics to those of DSM-III-R social phobics also lends support to the relaxation of the axis III exclusion in DSM-IV's definition of social phobia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195455

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  3 in total

Review 1.  Social anxiety disorder : current treatment recommendations.

Authors:  Jacqueline E Muller; Liezl Koen; Soraya Seedat; Dan J Stein
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  Social phobia in spasmodic torticollis.

Authors:  H Gündel; A Wolf; V Xidara; R Busch; A O Ceballos-Baumann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

3.  High social anxiety and poor quality of life in patients with pulmonary tuberculosis.

Authors:  Erkan Kibrisli; Yasin Bez; Ahmet Yilmaz; Hamza Aslanhan; Mahsuk Taylan; Halide Kaya; Abdullah Cetin Tanrikulu; Ozlem Abakay
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.